CD274 and non-small cell lung carcinoma: For example, Xing et al. conducted a phase I trial in patients with NSCLC, suggesting that anti-PD-L1-sdAb SPECT/CT using 99mTc-NM-01 could be used to closely monitor changes in PD-L1 expression during PD-L1 immunotherapy (Xing et al., 2019).